3M (MMM -2.47%) was once a dependable dividend stock for conservative investors. The diversified conglomerate sold a wide range of industrial, worker safety, and consumer goods, and it was a Dividend King which had raised its dividend annually for more than 50 years. It’s also been in the S&P 500 since the index’s inception in 1957.

But over the past three years, 3M’s stock declined about 12% as the S&P 500 rose 25%. It struggled with sluggish sales in a tough macro environment, while recalls and lawsuits exacerbated that pressure. It also ended its reign as a Dividend King in 2024 after it cut its payout and spun off its health care division as Solventum (SOLV -2.74%). Let’s see if this unloved blue chip stock can bounce back over the next three years.

3M Center in St. Paul.

Image source: 3M.

What happened to 3M over the past three years?

3M sells more than 60,000 products, including adhesives, abrasives, laminates, fire protection products, personal protective equipment, various types of films, insulation materials, car care products, and electronic circuits. Its top consumer brands include Scotch Tape, Scotchguard protectants, Post-It notes, and Nexcare bandages.

3M was growing at a healthy rate in 2021, but its organic sales growth slowed down significantly in 2022 and 2023 as its operating margins crumbled.

Metric

2021

2022

2023

Organic Sales Growth

8.8%

1.2%

(3.2%)

Operating Margin

20.8%

19.1%

(27.9%)

Data source: 3M.

The growth of its safety and industrial, transportation and electronics, and consumer businesses all stalled out in 2023 as it grappled with inflation, high interest rates, geopolitical conflicts, and other macro headwinds across the world. The only business which grew was its health care segment, which is now known as Solventum.

As 3M struggled to grow in that challenging market, it was hit by thousands of lawsuits for its production and dumping of PFAS (perfluoroalkyl and polyfluoroalkyl substances), which are also known as “forever chemicals”. 3M has already agreed to pay $14 billion in PFAS settlements so far, but the insurance giant AIG (AIG -1.30%) subsequently sued 3M and is refusing to cover any of those payments. It also needs to pay another $6 billion settlement from 2023 to 2029 related to a recall of its defective earplugs.

That mess is casting dark clouds over 3M’s future, since it ended its latest quarter with a negative operating cash flow of $1.8 billion, $11.3 billion in long-term debt, and just $7.3 billion in cash, cash equivalents, and marketable securities on its balance sheet. That’s why it underperformed the market by such a wide margin over the past three years.

What will happen to 3M over the next three years?

Last May, 3M brought in a new CEO, Bill Brown, to stabilize its wobbly business. Under Brown, 3M plans to shift some of its older products to faster-growing end markets, evaluate potential mergers or acquisitions, and streamline its R&D spending. It also aims to improve its supply chain visibility to avoid more costly quality control issues.

Those might be steps in the right direction, but 3M only expects its adjusted organic sales to grow about 1% in 2024 as its adjusted EPS (which includes its spin-off of Solventum but excludes its ongoing litigation expenses) declines 21%-22%. Therefore, it could take a few more years for those turnaround efforts to bear any visible fruit.

At $131, 3M might seem cheap at 17 times its forward adjusted earnings. But it trades at that discount because its growth is anemic, its business model is marred by serious safety and ethical concerns, and its turnaround plans are nebulous. Its forward dividend yield of 2.1% also won’t impress any income investors in this high interest rate market.

So while 3M isn’t doomed, I expect it to underperform the S&P 500 and many of its industry peers over the next three years. There simply aren’t enough compelling reasons to take a chance on this burnt-out blue chip stock.